Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Lenvatinib - Eisai Co Ltd/Merck & Co

Drug Profile

Lenvatinib - Eisai Co Ltd/Merck & Co

Alternative Names: E 7080; ER-203492-00; Kisplyx; KYSPLIX; Lenvatinib mesylate; LENVIMA; Lenvima; MK 7902

Latest Information Update: 11 Mar 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Eisai Co Ltd
  • Developer Curie Institute; Eisai Co Ltd; EMD Serono; Massachusetts Eye and Ear; Merck & Co; Merck Sharp & Dohme; MSD KK; National University Hospital (Singapore); Ono Pharmaceutical; SFJ Pharmaceuticals
  • Class Amides; Antineoplastics; Chlorobenzenes; Cyclopropanes; Eye disorder therapies; Phenyl ethers; Quinolines; Small molecules; Urea compounds
  • Mechanism of Action Platelet derived growth factor alpha receptor antagonists; Proto oncogene protein c ret inhibitors; Proto oncogene protein c-kit inhibitors; Type 1 fibroblast growth factor receptor antagonists; Type 3 fibroblast growth factor receptor antagonists; Type 4 fibroblast growth factor receptor antagonists; Type-2 fibroblast growth factor receptor antagonists; Vascular endothelial growth factor receptor 3 antagonists; Vascular endothelial growth factor receptor-1 antagonists; Vascular endothelial growth factor receptor-2 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Thyroid cancer; Liver cancer; Endometrial cancer; Malignant melanoma
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Endometrial cancer; Liver cancer; Renal cell carcinoma; Thyroid cancer
  • Registered Malignant thymoma
  • Phase III Colorectal cancer; Gastric cancer; Head and neck cancer; Malignant melanoma; Non-small cell lung cancer; Oesophageal cancer; Urogenital cancer
  • Phase II Biliary cancer; Glioblastoma; Kaposi's sarcoma; Malignant-mesothelioma; Neuroendocrine tumours; Osteosarcoma; Pancreatic cancer; Prostate cancer; Small cell lung cancer; Soft tissue sarcoma; Solid tumours; Uveal melanoma
  • Phase I/II Breast cancer
  • Phase I CNS cancer
  • No development reported Ovarian cancer
  • Discontinued Cancer; Glioma; Lymphoma

Most Recent Events

  • 18 Jan 2024 Efficacy and adverse events data from a phase II trial in Liver cancer presented at the 2024 Gastrointestinal Cancers Symposium (ASCo-GCS-2024)
  • 18 Jan 2024 Efficacy and adverse events data from a phase III trial in Hepatocellular carcinoma presented at the 2024 Gastrointestinal Cancers Symposium (ASCO-GCS-2024)
  • 08 Dec 2023 Efficacy and adverse events data from phase III LEAP-001 trial in Endometrial cancer released by Merck
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top